Core Viewpoint - 嘉事堂药业股份有限公司 is modifying its Independent Director Work System to align with updated legal regulations and business development needs, with the changes requiring approval at the upcoming shareholder meeting [1]. Summary by Sections Modifications to the Independent Director Work System - The company has proposed amendments to 11 articles of the Independent Director Work System [1]. - The specific details of the revisions are not listed in the announcement [1]. - The changes are in accordance with the Company Law (2023 Revision), the Guidelines for Listed Companies (2025 Revision), and the Shenzhen Stock Exchange Listing Rules [1]. Shareholder Involvement - Shareholders holding more than 1% of the company's issued shares can propose candidates for independent directors, subject to election by the shareholders' meeting [1]. - Nominators are prohibited from proposing candidates with whom they have a conflict of interest or other relationships that may affect the independent performance of duties [1]. - Investor protection agencies can publicly request shareholders to delegate their rights to nominate independent directors [1].
嘉事堂: 关于修订《独立董事工作制度》的公告